Franklin Limited Duration Income Trust Declares Monthly Dividend Sep 16, 2014 07:32PM

SAN MATEO, CA -- (Marketwired) -- 09/16/14 -- Franklin Limited Duration Income Trust (NYSE MKT: FTF), a closed-end investment company managed by Franklin Advisers, Inc., announced today a dividend of $0.062 per share, payable October 15, 2014, to shareholders of record on September 30, 2014 (Ex-Dividend Date: September 26, 2014).

Dividends may vary based on the Fund's net investment income. Past dividends are not indicative of future trends.

You may request a copy of the Fund's current Report to Shareholders by contacting Franklin Templeton's Fund Information Department at 1-800/DIAL BENŽ (1-800-342-5236) or by visiting All investments involve risks, including possible loss of principal. Interest rate movements and mortgage prepayments will affect the Fund's share price and yield. Bond prices generally move in the opposite direction of interest rates. As the prices of bonds in a fund adjust to a rise in interest rates, the fund's share price may decline. Investments in lower-rated bonds include higher risk of default and loss of principal. The Fund is actively managed but there is no guarantee that the manager's investment decisions will produce the desired results. For portfolio management discussions, including information regarding the Fund's investment strategies, please view the most recent Annual or Semi-Annual Report to Shareholders which can be found at or

Franklin Resources, Inc. (NYSE: BEN) is a global investment management organization operating as Franklin Templeton Investments. Franklin Templeton Investments provides global and domestic investment management to retail, institutional and sovereign wealth clients in over 150 countries. Through specialized teams, the Company has expertise across all asset classes -- including equity, fixed income, alternative and custom solutions. The Company's more than 600 investment professionals are supported by its integrated, worldwide team of risk management professionals and global trading desk network. With offices in 35 countries, the California-based company has more than 65 years of investment experience and over $922 billion in assets under management as of August 31, 2014. For more information, please visit

Franklin Templeton Investments
Shareholders/Financial Advisors:
(800) 342-5236

Source: Franklin Templeton

Introducing McGuire INSIGHTS, a Cutting-Edge Digital CMA and Agent Consulting Tool Sep 16, 2014 07:32PM

SAN FRANCISCO, CA -- (Marketwired) -- 09/16/14 -- McGuire Real Estate is very excited to announce McGuire INSIGHTS, a robust digital presentation and consulting tool, which provides our agents and their clients with access to the latest Bay Area market data anytime, anyplace.

McGuire INSIGHTS connects to all local MLS associations and features a fully interactive display of real-time market information that's easy to share via listing presentations and/or in everyday client communications. INSIGHTS allows McGuire Agents to be preferred sources and better-informed consultants, helping define and meet the needs of their clients. When equipped with INSIGHTS, agents can actually dispel common misconceptions touted by various real estate sites with factual MLS data, as well as have deeper and more in-depth conversations with both buyers and sellers.

The advantages of McGuire INSIGHTS:

  • Creates gorgeous full color presentations in minutes!
  • Pulls live, real-time data from local MLS (SFAR, BAREIS, EBRDI)
  • Generates more listings and leads for agents
  • Engages potential clients at open houses
  • Quickly narrows buyer search criteria
  • Interactive graphs, charts, and market recaps
  • Both web and iOS enabled - seamless iPad/iPhone app integration

A cloud-based tool, INSIGHTS allows McGuire agents to synch their presentations across all compatible devices. Whether using the web or iOS8 ready iPad/iPhone app, our agents know that they'll always have the latest version of their presentation ready, available, and complete with real-time market data. The possibilities with McGuire INSIGHTS are truly endless!

For more information about McGuire INSIGHTS, please contact

ABOUT MCGUIRE REAL ESTATE As a local, luxury boutique that focuses on the San Francisco Bay Area's high-end niche markets, McGuire Real Estate is a privately held corporation that was founded in 1919. We are headquartered in San Francisco's Marina District, with offices in Noe Valley, SOMA, Mill Valley, Berkeley, Burlingame and Sonoma. McGuire is the exclusive international associate of Savills PLC, headquartered in London, and is a broker member of Luxury PortfolioŽ International, and Leading Real Estate Companies of the WorldŽ, which connects our McGuire agents and clients to a world-wide marketplace.

Visit for more information or contact McGuire Client Care at 1.800.4RESULT and

Image Available:

Kate Stephenson
PR & Social Media Specialist
McGuire Real Estate
Email Contact

Source: McGuire Real Estate

NanoViricides Reports That Its CEO Dr. Seymour Will Be Interviewed about the Evolving Ebola Crisis on Fox Business News at 9PM EDT This Evening Sep 16, 2014 07:33PM

WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”), a nanomedicine company developing anti-viral drugs, reported that its CEO, Eugene Seymour, MD, MPH will be a guest on “The Independents”, a show on the Fox Business Channel this evening, airing at 9PM EDT.

He will discuss the current Ebola outbreak and the Company’s progress in developing an anti-Ebola drug for the treatment of patients infected with the Ebola virus.

He will also discuss some of the difficulties that could be encountered in attempts to bring the Ebola epidemic under control. Dr. Seymour has extensive field experience in the area of infectious diseases. He has previously worked on HIV/AIDS in Africa, Eastern Europe and Asia.

Currently, there are no approved drugs or vaccines against Ebola, although some vaccines as well as some drug candidates have entered clinical trials. The limitations of vaccines, antibodies, siRNA and oligonucleotide therapies are well known. A rapidly evolving virus such as the current Ebola virus can readily mutate such that these types of strain specific or narrow spectrum drugs may be rendered ineffective. In light of the paucity of available countermeasures, recently, the WHO has announced a policy for use of experimental drugs against Ebola to expedite drug availability.

NanoViricides, Inc. now has the capability of producing sufficient quantities of an anti-Ebola drug, after it is developed, for combating current and future Ebola epidemics. The highly customizable nanomedicine cGMP capable pilot scale manufacturing facility in Shelton, CT, will be able to supply all of the nanoviricides drug candidates in quantities needed for human clinical trials.

The Company has now developed novel drug candidates against Ebola that it believes could lead to a successful therapeutic. A nanoviricide® drug is made up of two components that are chemically connected together: a virus-binding ligand that mimics the native receptor on the host cell to which the virus binds, and a backbone polymer that makes the nanoviricide “look like” the host cell surface to the virus. There have been significant developments in the elucidation of the important cell surface receptors and attachment factors of Ebola virus recently. With this new structure based information, the Company has been able to redesign its anti-Ebola ligands using the scientific in silico drug design methodology.

The Honorable US President, Barak Obama has declared today that the World needs America to help defeat this epidemic Ebola virus, in a speech delivered at the CDC. “Faced with this outbreak, the world is looking to us, the United States, and it’s a responsibility that we embrace,” said the President. The U.S. has committed $500Million in defense spending on this “war on Ebola”, named Operation United Assistance, reported Time magazine online (

The current outbreak in Africa has unequivocally demonstrated the need for an effective, broad-spectrum, anti-Ebola therapeutic from which the mutating virus would not escape.

As of 10 September 2014, the World Health Organization (WHO) and the United States Centers for Disease Control and Prevention (CDC) reported a total of 4,846 suspected cases and 2,375 deaths, according to Wikipedia ( WHO has reported an overall measure of case fatality rate estimate of 52%, considerably lower than that reported from previous outbreaks. However, the actual case fatality rate based on following infected patients in a limited region was found to be about 77%. Unfortunately, this Ebola outbreak has continued to expand at an exponential rate in spite of significant efforts to contain it.

The Company is in negotiations with several parties regarding testing the new nanoviricide drug candidates against Ebola in the required high safety environments, i.e. BSL-4 facilities.

Because of the magnitude of the current outbreak, the Company restarted its EbolaCide development program. It had previously developed anti-Ebola drug candidates that demonstrated the validity and potential of the Company’s approach, based on cell culture and animal testing conducted at US Army Medical Research Institute of Infectious Diseases (USAMRIID) in a BSL-4 facility. The Company had to de-prioritize this development in order to focus on the development of its lead drug candidate, Injectable FluCide™, for treatment of hospitalized patients with influenza. The Company has recently reported that it has restarted its anti-Ebola/Marburg drug program, in consideration of the severe public health impact of an Ebola virus epidemic.

About NanoViricides:

NanoViricides, Inc. ( is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricideÂŽ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

NanoViricides, Inc.

Amanda Schuon, 310-550-7200

Source: NanoViricides, Inc.

Customer Experience and Conversion Expert to Present on Eye Tracking and Emotional Testing at Annual Summit Sep 16, 2014 07:32PM

CLEVELAND, OH -- (Marketwired) -- 09/16/14 -- As famed musician Frank Zappa once stated regarding emotion, "The computer can't tell you the emotional story. It can give you the exact mathematical design, but what's missing is the eyebrows." With recent advancements in research and technology this saying is no longer true. During the Annual Summit, retailers will have the opportunity to attend breakout session "Behavioral, Eye Tracking and Emotional Testing -- Maximizing Insights to Improve the User Experience" in which they will learn how recent advancements in groundbreaking emotional testing technology can detect subconscious user emotional states and be used to tell the user experience story. 

Cathleen Zapata, Chief Experience Officer at Precision Dialogue will be co-presenting with client Jennifer Biefel, Manager, CRM Program Management at Disney Parks and Laura McFadden, User Experience Architect at Arhaus Furniture. The trio will be presenting on usability testing, usability testing with eye tracking and emotional testing techniques.

Additionally, requested to participate for the fourth year in a row, Zapata will be one of the "doctors" providing expert evaluations in the popular "Doctor Is In: One-on-One Website Critiques" session during the retailer conference. She will be providing 30 minute private one-on-one consultations with registered retailers focused on how to improve the user experience and conversion.

"Usable websites are no longer a differentiator, but rather, an expectation by users. In order to leapfrog the competition, retailers need to not only ensure the site is usable, but that it motivates and persuades users to take action and have an overall pleasant experience," explained Zapata. "Evaluating not only what your user's say and do, but also, what they see and feel, allows you to identify conversion barriers and streamline the buying process."

Cathleen Zapata is currently the Chief Experience Officer at Precision Dialogue where she manages the Research & Customer Experience division's accounts, service offerings, lab and team. She has nearly 20 years' experience working with clients to improve their customer's experiences balanced with business goals to maximize ROI. 

Cathy has been published in numerous industry publications including UX Magazine, BAI Retail Delivery and Quirk's Marketing Research Review. She has worked with clients across industries including Disney, American Greetings, Four Seasons, OfficeMax, Coach, Inc., CVS, KeyBank, Nationwide Insurance and more.

Retailers will also be able to connect with Zapata and others from the Precision Dialogue team at Precision Dialogue's booth (#1503) in the expo hall. At the booth, you can test the eye tracking and wireless EEG equipment. Precision Dialogue is the only customer engagement firm nationwide with a full suite of owned in-lab and mobile eye tracking as well as emotional tracking capabilities via EEG.

Precision Dialogue is also participating in the big prize giveaway sponsorship and will be giving away a $4,000 Apple Vacations gift certificate. Annual Summit is the digital retail industry's premier event where thousands of executives gather with the common purpose of advancing their industry through the sharing of knowledge, experience and expertise. To learn more about Annual Summit, visit 

To learn more about Precision Dialogue's Research and Customer Experience solutions, visit 

Precision Dialogue is a vertically integrated customer engagement firm with a proven methodology for mining and analyzing customer insights and behaviors to create targeted personalized communication through a variety of integrated online and offline channels. Anchored by a focused vision and progressive history, the company has become a leading full service end-to-end marketing solution provider uniquely positioned to manage the radically evolving demands of this new era of consumer and business marketing. To learn more about Precision Dialogue, visit

The following files are available for download:

   Nathan EnzerraMarketing CoordinatorPrecision DialogueNathan.Enzerra@precisiondialogue.com440.471.6871 x 279

Source: Precision Dialogue

ROX Medical presents positive data for CONTROL-HTN resistant hypertension trial Sep 16, 2014 07:30PM

SAN CLEMENTE, Calif., Sept. 16, 2014 /PRNewswire/ -- ROX Medical today presented positive results from the CONTROL-HTN trial, an international multi-center, prospective, randomized, controlled, blinded endpoint study of the ROX Coupler for the treatment of arterial hypertension. The CONTROL-HTN trial, NCT01642498, evaluated the safety and efficacy of a percutaneous procedure creating a fixed connection between a central artery and vein in the upper leg - for the treatment of hypertension. The primary outcomes are reduction of blood ambulatory blood pressure and office pressure at 6 months post procedure as well as the safety and efficacy of the ROX Coupler. 

The CONTROL-HTN results were presented by study Principal Investigator, Mel Lobo, MD of St Bartholomew's and the London NHS Trust (Barts) on behalf of the study investigators. The results showed a statistically significant reduction of Office blood pressure in the treatment group of -23/-17mmHg and a reduction of 24 hr Ambulatory blood pressure of -12/-13mmHg. In addition, the trial revealed a statistically significant reduction of hospitalized hypertensive crisis events in the treatment versus control group. A pre-specified sub-group of patients who had previously received renal denervation also demonstrated a statistically significant reduction in both office BP of -34/-15mmHg and Ambulatory BP of -14/-17mmHg. Additionally, the treatment group experienced a significant reduction of their hypertensive medications whereas the control group required significant increases in their hypertensive medications.

"We are very pleased to have completed a high quality trial that shows an immediate and significant reduction in blood pressure and importantly reduces the risk of hospitalized hypertensive crisis", commented Dr Lobo, "we are in need of additional tools for addressing uncontrolled hypertension."

ROX Medical's FLOW procedure is a minimally invasive catheter based procedure performed by interventional cardiologists, radiologists and vascular surgeons in under one hour. The ROX Coupler is placed between the iliac artery and vein in the upper leg creating a fixed volume pressure relief. This results in an immediate reduction of blood pressure, vascular resistance and increased arterial compliance.

"The delivery of a safe, confirmable therapy with immediate response should provide gratification to patients and physicians alike" commented Paul A. Sobotka, MD, Chief Scientific Officer of ROX Medical, "this demonstrates the importance of non compliant or stiff artery to the pathology of hypertension and broadens the potential therapeutic landscape for chronic hypertension. "

The ROX FLOW procedure for hypertension is not approved for use in the U.S.

Logo -


More Press Releases

View Older Stories

Sep 16, 2014 07:30PM CallidusCloud Acquires UK-Based Clicktools, Adds Enterprise Survey and CRM Integration Capability to the Award-Winning Lead To Money Suite
Sep 16, 2014 07:29PM Gorman & Company, Inc. Partners With Town Of Vail And Wright And Company To Build 112 Unit Deed-Restricted Employee Housing In Vail, Marking Vail's Largest Employee Housing Project Ever
Sep 16, 2014 07:25PM Xactly CMO Scott Broomfield Discusses Marketing Automation Revolution at Ad Age Digital
Sep 16, 2014 07:24PM Blueknight Energy Partners Prices Public Offering of Common Units
Sep 16, 2014 07:20PM CORRECTION FROM SOURCE/Gamehost Declares Regular Monthly Dividend for September 2014
Sep 16, 2014 07:17PM PNM Resources Board Declares Quarterly Common Stock Dividend
Sep 16, 2014 07:15PM Microsoft announces board changes and quarterly dividend increase
Sep 16, 2014 07:15PM Steinger, Iscoe & Greene Fund School Mascot
Sep 16, 2014 07:15PM Grant Victor Hires New Senior Vice President of Technology, Director of Marketing
Sep 16, 2014 07:12PM Los Angeles Youth Network Launches New Home For Foster & Homeless Youth
Sep 16, 2014 07:11PM Tuckamore Notified of Possible Indemnity Claim by Brompton Corp.
Sep 16, 2014 07:10PM BlueHost and Are Among the Best Hosting Suppliers in 2014
Sep 16, 2014 07:00PM Daddy Yankee Featured in Music Choice's Play Chronicles
Sep 16, 2014 07:00PM New Brighton Implant Clinic Opens In Worthing
Sep 16, 2014 07:00PM Affordable Insurance for Car Owners Now Found Through Linked Database Online
Sep 16, 2014 07:00PM REVA Presents Fantom Scaffold Program at TCT 2014 Conference
Sep 16, 2014 06:59PM Super Nova Petroleum Corp.: Closing of Private Placement of 1,791,474 Units at $0.05
Sep 16, 2014 07:00PM Ability Commerce Named a Top e-Retail Vendor by Internet Retailer
Sep 16, 2014 07:00PM REVA Presents Fantom Scaffold Program at TCT 2014 Conference
Sep 16, 2014 07:00PM Global Diamond Demand Reaches Record Levels
Sep 16, 2014 07:00PM Thailand's SCB Asset Management Live on Multi-Asset Charles River IMS
Sep 16, 2014 06:59PM Alterra Power Corp.: News Release
Sep 16, 2014 06:51PM Improved risk identification will aid fertility preservation in young male cancer patients
Sep 16, 2014 06:51PM $5.5 Million Settlement in False Claims Act Case Filed by Minnesota Whistleblower
Sep 16, 2014 06:50PM CVB Financial Corp. to Present at Investor Meetings in Boston with FIG Partners
Sep 16, 2014 06:47PM NHTSA Needs Critical Reforms and Increased Resources to Protect Consumers
Sep 16, 2014 06:45PM Viverae Acquires OneHealth to Create a Full-Spectrum Wellness Platform
Sep 16, 2014 06:43PM CBS Outdoor Announces Pricing of Senior Notes Offering
Sep 16, 2014 06:38PM Realty Income To Redeem All Outstanding Shares Of 6.75% Monthly Income Class E Preferred Stock
Sep 16, 2014 06:38PM Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Glimcher Realty Trust Stockholders
Sep 16, 2014 06:36PM Platinum Communications Stock Option Grants
Sep 16, 2014 06:33PM Tower International Postpones Proposed Offering of $250 Million Senior Unsecured Notes
Sep 16, 2014 06:32PM CORRECTION - Focus Holdings Is Now Team Focus Insurance Group
Sep 16, 2014 06:31PM September 2014 Release of Appmethod Supports Internet of Things, Including Wearables Such as Google Glass
Sep 16, 2014 06:30PM Local Rainbow InternationalÂŽ Business Receives International Award
Sep 16, 2014 06:30PM Fitch Downgrades IMPSA/WPEI/Venti's IDRs to 'C'
Sep 16, 2014 06:30PM Highland/iBoxx Senior Loan ETF Announces Details of September Regular Distribution
Sep 16, 2014 06:30PM Premier Business Centers Adds Second Location in the Del Mar Area of San Diego
Sep 16, 2014 06:23PM Leader of Reputation Management Defines Content Marketing
Sep 16, 2014 06:23PM Biocom Recognizes National Health IT Week
Sep 16, 2014 06:23PM Gamehost Declares Regular Monthly Dividend for September 2014
Sep 16, 2014 06:21PM Black Shopping Channel, (BSC) Signs $125 Million Deal to Expand TV Viewership
Sep 16, 2014 06:21PM AHF Joins National Coalition on Health Care’s ‘Campaign for Sustainable Rx Pricing’
Sep 16, 2014 06:20PM Howell Motors Ford Celebrates 100 Years in One Community
Sep 16, 2014 06:20PM Lawsuit by Association of American Physicians and Surgeons (AAPS) Challenging Obama's Rewriting of ObamaCare Heard in Chicago
Sep 16, 2014 06:20PM Cliff Lake Dental Care Announces Newest Team Member
Sep 16, 2014 06:18PM Exar Completes Merger with Integrated Memory Logic
Sep 16, 2014 06:18PM Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Name Interim Chief Information Officer
Sep 16, 2014 06:17PM Arizona Commerce Authority and Arizona Technology Council Launch the new TechConnect: Arizona's Technology Magazine
Sep 16, 2014 06:15PM AbiliTrax Exceeds Testing Requirements for Mercedes Sprinter Seating
View Older Stories